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In the last decades we have seen a rapid expansion of the
proportion of obese individuals worldwide. Actually obesity
has gradually but also rather considerably revealed as a
whole medical problem with menacing implications for the
health of our society. Indeed, obesity is already of epidemic
proportions in the U.S. and in many other parts of the world
and it is a worrying problem also in developing countries.
According to the last data of World Health Organization,
more than 1 billion people are overweight worldwide, where
more than 300 million fulﬁl obesity criteria [1]. Obesity
is accompanied by a plethora of other relevant diseases
including cardiovascular, cerebrovascular, and liver diseases,
type 2 diabetes, and dyslipidemias that are aﬀecting also
youngestagegroupsofpopulation.Obesityhasbeenrecently
recognized also as a relevant contributing risk factor for
certain types of cancer [2].
Emerging literaturesuggeststhatinﬂammation, asevalu-
atedbyhighinﬂammatorycytokineslevelsandotherinﬂam-
matory markers, may represent basically a cause and conse-
quence of obesity and its comorbidities [3]. We have to bear
in mind that obesity is a consequence of millions of years of
evolution during which the ability to store eﬃciently fat in
long periods of ﬂuctuation of food availability, alternated by
famines, granted capacity to survive, reproduce, and main-
tain survival of oﬀspring. In the last 50 years, characterized
by an excess of food availability, this adaptive skill shifted
to maladaptive increasing the propensity to obesity and
its comorbidities above mentioned. Several disorders that
represent the major sources of morbidity and mortality in
the present world such as type 2 diabetes, cardiovascular
disease, and cancer are known to be associated with obe-
sity and have recently been reconsidered as inﬂammatory
diseases. For instance, the inﬂammation associated with
the accumulation of intra-abdominal fat is associated with
progressive resistance to the eﬀects of insulin, ultimately
leading to type 2 diabetes [4]. Anyway, the causes for the
activation of the inﬂammatory response in obesity and its
comorbidities are undoubtedly complex and we are in the
beginning of the road to cover. Indeed, increasing evidence
(most of them reported in this special issue) suggests a
possible causal link between adiposity, particularly visceral
obesity and inﬂammation. Obesity leads to increases in
inﬂammatory cytokines and adipocytokines and changes in
related molecules such as leptin and adiponectin, which
may contribute to the development of multiple disturbs in
predisposedindividuals.However,inmostcasestherelation-
ship appears to be bi-directional, in that prior comorbidities
seem to increase and perpetuate the proinﬂammatory status
associated to adiposity. Clearly, more research is needed to
examine the complex interplay between inﬂammation and
adiposity, an eﬀect that is also in part to consequences of
lowphysicalactivity.However,theinteractionsbetweenthese
systems oﬀer unique opportunities for targeted treatment
and prevention strategies.
For instance, there is a pressing need to investigate
strategies to disrupt inﬂammatory signalling in persons
with obesity (morbid or not) who show indication of
a proinﬂammatory state (e.g., those with elevated CRP).
Research on approaches that alter diet, increasing the intake
of particular micronutrients, or, of course, reducing weight,
is also needed [5].
This special issue has focused on adiposity and inﬂam-
mation as one of the main contributing factors for obesity-
associated morbidities.
However, several salient facts must be noted. Obesity
and comorbidities are complex and multifaceted diseases2 Mediators of Inﬂammation
with too many contributing factors. So, here we intended to
suggest that inﬂammation and adiposity contribute strongly
in all or even most aﬀected people. The prevention of obesity
would signiﬁcantly reduce the burden of comorbid diseases.
Indeed, by decreasing prevalence of obesity, other obesity-
related conditions can be reduced to a greater extent and
this will help in cutting down the health care budget to a
g r e a te x t e n t( i nt i m e so fe c o n o m i cc r i s i sa ss u c hw ea r el i v i n g
everywhere, this should be mandatory considered).
One year ago approximately, I answered to a call of
our Editor in Chief, Professor Freek Zijlstra, suggesting a
special issue on mediators of inﬂammation in obesity and its
comorbidities, and he has indeed selected a worthy topic.
InthisissueofMediatorsofInﬂammation,wearepleased
to present to the reader a series of special features written by
great authorities in the ﬁeld. In this special issue, the reader
w i l lﬁ n ds e v e r a la r t i c l e s( m o r et h a n2 5 )w r i t t e nb ye x p e r t s
on epidemiology, mechanisms and molecules, regulation
of body weight, concomitants of obesity, and therapeutic
approaches to obesity.
I would like to thank all contributors and reviewers and
I am personally grateful for your support to this special issue
as there can be no growth or improvement without your
participation.
Finally,aspecialthankisalsoduetotheAssociateEditors
of this special issue Giamila Fantuzzi, Gema Fruhbeck,
Giuseppe Matarese, and Paul Trayhurn for their hard work,
commitment, and support.
Oreste Gualillo
References
[1] “Obesity: preventing and managing the global epidemic,”
Report of a WHO Consultation 894, World Health Organiza-
tion, Geneva, Switzerland, 2000, http://whqlibdoc.who.int/trs/
WHO TRS 894.pdf.
[2] K. B. Schelber, “Comorbidities of obesity,” Primary Care, vol.
36, no. 2, pp. 271–285, 2009.
[3] M. Otero, R. Lago, F. Lago et al., “Leptin, from fat to
inﬂammation: old questions and new insights,” FEBS Letters,
vol. 579, no. 2, pp. 295–301, 2005.
[4] R. W. O’Rourke, “Molecular mechanisms of obesity and
diabetes:attheintersectionofweightregulation,inﬂammation,
and glucose homeostasis,” World Journal of Surgery, vol. 33, no.
10, pp. 2007–2013, 2009.
[5] F. Branca, H. Nikogosian, and T. Lobstein, Eds., The Challenge
of Obesity in the WHO European Region and the Strategies for
Response, EURO, 2007.